GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » EV-to-FCF

Radiopharm Theranostics (ASX:RAD) EV-to-FCF : -0.58 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Radiopharm Theranostics's Enterprise Value is A$14.22 Mil. Radiopharm Theranostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-24.40 Mil. Therefore, Radiopharm Theranostics's EV-to-FCF for today is -0.58.

The historical rank and industry rank for Radiopharm Theranostics's EV-to-FCF or its related term are showing as below:

ASX:RAD' s EV-to-FCF Range Over the Past 10 Years
Min: -1.08   Med: 0   Max: 1.51
Current: -0.6

During the past 2 years, the highest EV-to-FCF of Radiopharm Theranostics was 1.51. The lowest was -1.08. And the median was 0.00.

ASX:RAD's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs ASX:RAD: -0.60

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Radiopharm Theranostics's stock price is A$0.035. Radiopharm Theranostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.136. Therefore, Radiopharm Theranostics's PE Ratio for today is At Loss.


Radiopharm Theranostics EV-to-FCF Historical Data

The historical data trend for Radiopharm Theranostics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics EV-to-FCF Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
EV-to-FCF
-0.39 -1.17

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF - - - - -

Competitive Comparison of Radiopharm Theranostics's EV-to-FCF

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-FCF falls into.



Radiopharm Theranostics EV-to-FCF Calculation

Radiopharm Theranostics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=14.219/-24.395
=-0.58

Radiopharm Theranostics's current Enterprise Value is A$14.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-24.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (ASX:RAD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Radiopharm Theranostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.035/-0.136
=At Loss

Radiopharm Theranostics's share price for today is A$0.035.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.136.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Radiopharm Theranostics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (ASX:RAD) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines